By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Amunix, Inc. 

500 Ellis Street
Suite B
Mountain View  California  94043  U.S.A.
Phone: 650-428-1800 Fax: n/a




Company News
Amunix, Inc. Release: IND Submission To Initiate Clinical Trials Of NB 1001 (XTEN-GLP1) For Treatment Of Short Bowel Syndrome Announced By Naia Rare Diseases 12/19/2016 1:15:42 PM
Amunix, Inc. Establishes GMP Manufacturing Of XTEN At UN-L BPDF 11/17/2015 12:45:26 PM
Amunix, Inc. Establishes GMP Manufacturing Of XTENTM At UN-L BPDF 11/16/2015 11:24:22 AM
Amunix, Inc. Announces Extension Of Evaluation Agreement With Roche (RHHBY) 10/26/2015 10:10:34 AM
Bay Area's Amunix, Inc. Strikes $70 Million+ Deal With Naia 1/5/2015 6:17:30 AM
Amunix, Inc. Announces Option Exercise By Eli Lilly (LLY) For XTEN™ Product For People With Diabetes 12/18/2014 11:25:31 AM
Amunix, Inc. And PolyPeptide Laboratories Inc. Enter Into Partnership To Produce XTEN™ Peptide Conjugates For Evaluation By Third Parties For Pharmaceutical Therapeutics 10/28/2014 10:40:53 AM
Amunix, Inc. Signs A Services And Supply Agreement With The University Of Nebraska-Lincoln To Produce GMP-Grade XTEN™ For Pharmaceutical Therapeutics 10/27/2014 11:12:28 AM
Amunix, Inc. And PolyPeptide Publish Multivalent Antiviral XTEN-Peptide Conjugates In Vivo Studies In American Chemical Society's Journal 7/24/2014 1:11:10 PM
Amunix, Inc. Congratulates Versartis, Inc. (VSAR) On Its Positive Phase 2a Results With VRS-317 6/30/2014 11:13:03 AM